What plasma concentration defines quetiapine (Seroquel) toxicity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Quetiapine Toxic Level

There is no universally defined plasma concentration that defines quetiapine toxicity, but postmortem and overdose data suggest that blood concentrations above 1.0 mg/L (therapeutic range: 0.1-1.0 mg/L) are associated with toxicity, with fatal overdoses typically occurring at concentrations of 5.9-16 mg/L or higher.

Understanding Quetiapine Toxicity

The therapeutic range for quetiapine in serum is 0.1-1.0 mg/L based on steady-state pharmacokinetic studies 1. However, defining a specific "toxic level" is challenging because:

Fatal Overdose Data

Research from postmortem cases provides the most concrete data on toxic concentrations:

  • Fatal overdose range: Blood concentrations of 5.9-16 mg/L have been documented in fatal quetiapine overdoses 2
  • One study reported an average blood concentration of 7.95 mg/L (range 0.4-76 mg/L) in 18 cases where quetiapine contributed to death 3
  • Individual fatal cases have shown concentrations as high as 49 mg/L in heart blood 4

Clinical Toxicity Threshold

Blood concentrations 6-16 times greater than the upper therapeutic range (i.e., above 6 mg/L) are consistently associated with serious toxicity 2. However, toxicity can occur at lower concentrations depending on individual factors and co-ingestions.

Clinical Manifestations of Overdose

According to FDA labeling, quetiapine overdose presents with exaggeration of known pharmacological effects 5:

  • CNS effects: Drowsiness, sedation, coma, delirium
  • Cardiovascular effects: Tachycardia, hypotension, QT prolongation (in overdose), first-degree heart block
  • Anticholinergic toxicity
  • One case involving 9,600 mg resulted in hypokalemia and heart block 5

Critical caveat: Patients with pre-existing cardiovascular disease face increased risk from overdose effects 5. Death has been reported with as little as 13.6 grams in clinical trials 5.

Blood-to-Serum Considerations

When interpreting whole blood concentrations (common in postmortem cases), apply a conversion factor:

  • Blood:serum ratio = 0.74 (95% CI: 0.71-0.76) 6
  • Quetiapine concentrations are consistently lower in whole blood than serum due to high plasma protein binding
  • To extrapolate serum concentrations from whole blood, divide by approximately 0.7

Tissue Distribution in Toxicity

In fatal cases, quetiapine shows extensive tissue distribution 3:

  • Liver: Mean 91 mg/kg (range 1.1-510 mg/kg)
  • Bile: Mean 44 mg/L (range 6.0-96 mg/L)
  • Gastric contents: Up to 3,960 mg total
  • Vitreous humor: Mean 1.4 mg/L (range 0.2-3.2 mg/L)

Management Approach

Per FDA guidelines 5:

  1. Establish and maintain airway with adequate oxygenation/ventilation
  2. Continuous ECG monitoring to detect arrhythmias (especially QT prolongation)
  3. Supportive measures are the mainstay
  4. Contact Poison Control (1-800-222-1222) for current management guidance

No specific antidote exists for quetiapine overdose. Treatment is entirely supportive.

Key Clinical Pitfalls

  • Co-ingestions are common: Most fatal quetiapine cases involve multiple drugs 3, 2. Never assume quetiapine is the sole toxin.
  • Delayed toxicity: Survival has been reported with acute overdoses up to 30 grams, but death occurred with 13.6 grams in one case 5. Clinical course is unpredictable.
  • Cardiovascular monitoring is essential: QT prolongation and arrhythmias are documented complications of overdose 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.